This is the authors' abstract. We don't add key points for this paper.
Figure S2. Comparison of CIR stratified by the different timepoint post treatment residual status either of plasma ctDNA (A-C) or mutation in BM (D-F). CIR according to residual status either of plasma ctDNA (A) or mutation in BM (D) at C2D1 post treatment; CIR according to residual status either of plasma ctDNA (B) or mutation in BM (E) at C3D1 post treatment; CIR according to residual status either of plasma ctDNA (C) or mutation in BM (F) at C4D1 post treatment. A higher CIR was associated with patients with ctDNA or BM DNA positive results at any point (all p<0.001). BM, bone marrow; CIR, cumulative incidence of relapse; C2D1, Cycle 2 day 1; C3D1, Cycle 3 day 1; C4D1, Cycle 4 day 1
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: